A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumours
This is a multicentre, open-label, dose-exploration and dose-expansion study to evaluate the
safety, tolerability, antitumour activity, PK and immunogenicity of MEDI4736 in combination
with tremelimumab in subjects with select advanced solid tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society